Veeva Systems Soars with Strategic Partnerships

Veeva Systems (VEEV) is making strategic partnerships in clinical trials, AI tools, and regulatory tech to drive growth. Recent deals with Astellas and Sarah Cannon have boosted VEEV shares by 33.5% YTD, outpacing the industry. The company’s partnerships are helping drive adoption, deepen customer relationships, and unlock new growth opportunities across various sectors. VEEV trades at a forward price-to-sales ratio of 14.25, with a Value Score of D. The Zacks Consensus Estimate for VEEV’s fiscal 2026 earnings suggests a 15.8% increase from the previous year. VEEV currently holds a Zacks Rank #3 (Hold).

Read more at Zacks Investment Research: Veeva Expands Market Reach Through Targeted Strategic Partnerships – July 9, 2025